Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Resveratrol and Human Hepatocyte Function in Cancer
Resveratrol and Human Hepatocyte Function in Cancer
Status: Enrolling
Updated:  6/13/2016
University of Louisville
mi
from
Louisville, KY
Resveratrol and Human Hepatocyte Function in Cancer
Resveratrol and Human Hepatocyte Function in Cancer
Status: Enrolling
Updated: 6/13/2016
University of Louisville
mi
from
Louisville, KY
Click here to add this to my saved trials
AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine
A Phase II Study of AZD2171 in Adult Patients With Neurofibromatosis Type 1 and Extensive Plexiform and Paraspinal Neurofibromas
Status: Enrolling
Updated:  6/14/2016
Case Western Reserve Univ
mi
from
Cleveland, OH
AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine
A Phase II Study of AZD2171 in Adult Patients With Neurofibromatosis Type 1 and Extensive Plexiform and Paraspinal Neurofibromas
Status: Enrolling
Updated: 6/14/2016
Case Western Reserve Univ
mi
from
Cleveland, OH
Click here to add this to my saved trials
AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine
A Phase II Study of AZD2171 in Adult Patients With Neurofibromatosis Type 1 and Extensive Plexiform and Paraspinal Neurofibromas
Status: Enrolling
Updated:  6/14/2016
University of Alabama at Birmingham Cancer Center
mi
from
Birmingham, AL
AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine
A Phase II Study of AZD2171 in Adult Patients With Neurofibromatosis Type 1 and Extensive Plexiform and Paraspinal Neurofibromas
Status: Enrolling
Updated: 6/14/2016
University of Alabama at Birmingham Cancer Center
mi
from
Birmingham, AL
Click here to add this to my saved trials
AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine
A Phase II Study of AZD2171 in Adult Patients With Neurofibromatosis Type 1 and Extensive Plexiform and Paraspinal Neurofibromas
Status: Enrolling
Updated:  6/14/2016
Howard University Hospital
mi
from
Washington,
AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine
A Phase II Study of AZD2171 in Adult Patients With Neurofibromatosis Type 1 and Extensive Plexiform and Paraspinal Neurofibromas
Status: Enrolling
Updated: 6/14/2016
Howard University Hospital
mi
from
Washington,
Click here to add this to my saved trials
AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine
A Phase II Study of AZD2171 in Adult Patients With Neurofibromatosis Type 1 and Extensive Plexiform and Paraspinal Neurofibromas
Status: Enrolling
Updated:  6/14/2016
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine
A Phase II Study of AZD2171 in Adult Patients With Neurofibromatosis Type 1 and Extensive Plexiform and Paraspinal Neurofibromas
Status: Enrolling
Updated: 6/14/2016
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine
A Phase II Study of AZD2171 in Adult Patients With Neurofibromatosis Type 1 and Extensive Plexiform and Paraspinal Neurofibromas
Status: Enrolling
Updated:  6/14/2016
Massachusetts General Hospital Cancer Center
mi
from
Boston, MA
AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine
A Phase II Study of AZD2171 in Adult Patients With Neurofibromatosis Type 1 and Extensive Plexiform and Paraspinal Neurofibromas
Status: Enrolling
Updated: 6/14/2016
Massachusetts General Hospital Cancer Center
mi
from
Boston, MA
Click here to add this to my saved trials
AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine
A Phase II Study of AZD2171 in Adult Patients With Neurofibromatosis Type 1 and Extensive Plexiform and Paraspinal Neurofibromas
Status: Enrolling
Updated:  6/14/2016
Dana-Farber / Harvard Cancer Center
mi
from
Boston, MA
AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine
A Phase II Study of AZD2171 in Adult Patients With Neurofibromatosis Type 1 and Extensive Plexiform and Paraspinal Neurofibromas
Status: Enrolling
Updated: 6/14/2016
Dana-Farber / Harvard Cancer Center
mi
from
Boston, MA
Click here to add this to my saved trials
AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine
A Phase II Study of AZD2171 in Adult Patients With Neurofibromatosis Type 1 and Extensive Plexiform and Paraspinal Neurofibromas
Status: Enrolling
Updated:  6/14/2016
Wayne State University/Karmanos Cancer Institute
mi
from
Detroit, MI
AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine
A Phase II Study of AZD2171 in Adult Patients With Neurofibromatosis Type 1 and Extensive Plexiform and Paraspinal Neurofibromas
Status: Enrolling
Updated: 6/14/2016
Wayne State University/Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine
A Phase II Study of AZD2171 in Adult Patients With Neurofibromatosis Type 1 and Extensive Plexiform and Paraspinal Neurofibromas
Status: Enrolling
Updated:  6/14/2016
The Mayo Clinic
mi
from
Rochester, MN
AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine
A Phase II Study of AZD2171 in Adult Patients With Neurofibromatosis Type 1 and Extensive Plexiform and Paraspinal Neurofibromas
Status: Enrolling
Updated: 6/14/2016
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine
A Phase II Study of AZD2171 in Adult Patients With Neurofibromatosis Type 1 and Extensive Plexiform and Paraspinal Neurofibromas
Status: Enrolling
Updated:  6/14/2016
Washington University School of Medicine
mi
from
Saint Louis, MO
AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine
A Phase II Study of AZD2171 in Adult Patients With Neurofibromatosis Type 1 and Extensive Plexiform and Paraspinal Neurofibromas
Status: Enrolling
Updated: 6/14/2016
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Docetaxel, Gemcitabine and Pazopanib as Treatment for Soft Tissue Sarcoma
Phase I/II Study of the Combination of Docetaxel, Gemcitabine and Pazopanib for Neoadjuvant Treatment of Patients With Operable Soft Tissue Sarcoma
Status: Enrolling
Updated:  6/14/2016
Fletcher Allen Health Care
mi
from
Burlington, VT
Docetaxel, Gemcitabine and Pazopanib as Treatment for Soft Tissue Sarcoma
Phase I/II Study of the Combination of Docetaxel, Gemcitabine and Pazopanib for Neoadjuvant Treatment of Patients With Operable Soft Tissue Sarcoma
Status: Enrolling
Updated: 6/14/2016
Fletcher Allen Health Care
mi
from
Burlington, VT
Click here to add this to my saved trials
Educational Intervention for Reducing Work Disability in Breast Cancer Survivors
Reducing Work Disability in Breast Cancer Survivors
Status: Enrolling
Updated:  6/14/2016
University of Wisconsin Hospital and Clinics
mi
from
Madison, WI
Educational Intervention for Reducing Work Disability in Breast Cancer Survivors
Reducing Work Disability in Breast Cancer Survivors
Status: Enrolling
Updated: 6/14/2016
University of Wisconsin Hospital and Clinics
mi
from
Madison, WI
Click here to add this to my saved trials
Patient Navigation in the Safety Net:CONNECTeDD
Patient Navigation in the Safety Net:CONNECTeDD
Status: Enrolling
Updated:  6/14/2016
Boston Med Ctr
mi
from
Boston, MA
Patient Navigation in the Safety Net:CONNECTeDD
Patient Navigation in the Safety Net:CONNECTeDD
Status: Enrolling
Updated: 6/14/2016
Boston Med Ctr
mi
from
Boston, MA
Click here to add this to my saved trials
Adaptive MRI-Guided SBRT for Unresectable Primary or Oligometastatic Central Thorax and Abdominal Malignancies
Pilot Study of Online, Adaptive MRI-Guided SBRT for Unresectable Primary or Oligometastatic Central Thorax and Abdominal Malignancies
Status: Enrolling
Updated:  6/15/2016
Washington University School of Medicine
mi
from
St. Louis, MO
Adaptive MRI-Guided SBRT for Unresectable Primary or Oligometastatic Central Thorax and Abdominal Malignancies
Pilot Study of Online, Adaptive MRI-Guided SBRT for Unresectable Primary or Oligometastatic Central Thorax and Abdominal Malignancies
Status: Enrolling
Updated: 6/15/2016
Washington University School of Medicine
mi
from
St. Louis, MO
Click here to add this to my saved trials
Trial of Anti-PSMA Designer T Cells in Advanced Prostate Cancer After Non-Myeloablative Conditioning
Phase Ia/Ib Trial of Anti-PSMA Designer T Cells in Advanced Prostate Cancer After Non-Myeloablative Conditioning
Status: Enrolling
Updated:  6/16/2016
Roger Williams Medical Center
mi
from
Providence, RI
Trial of Anti-PSMA Designer T Cells in Advanced Prostate Cancer After Non-Myeloablative Conditioning
Phase Ia/Ib Trial of Anti-PSMA Designer T Cells in Advanced Prostate Cancer After Non-Myeloablative Conditioning
Status: Enrolling
Updated: 6/16/2016
Roger Williams Medical Center
mi
from
Providence, RI
Click here to add this to my saved trials
Trial of Second Generation Designer T Cells in Colorectal Carcinoma
Phase II/Pilot Trial of Second Generation Designer T Cells in Colorectal Cancer
Status: Enrolling
Updated:  6/16/2016
Roger Williams Medical Center
mi
from
Providence, RI
Trial of Second Generation Designer T Cells in Colorectal Carcinoma
Phase II/Pilot Trial of Second Generation Designer T Cells in Colorectal Cancer
Status: Enrolling
Updated: 6/16/2016
Roger Williams Medical Center
mi
from
Providence, RI
Click here to add this to my saved trials
Trial of 2nd Generation Anti-CEA Designer T Cells in Metastatic Breast Cancer
Phase Ia/Ib Trial of 2nd Generation Anti-CEA Designer T Cells in Metastatic Breast Cancer
Status: Enrolling
Updated:  6/16/2016
Roger Williams Medical Center
mi
from
Providence, RI
Trial of 2nd Generation Anti-CEA Designer T Cells in Metastatic Breast Cancer
Phase Ia/Ib Trial of 2nd Generation Anti-CEA Designer T Cells in Metastatic Breast Cancer
Status: Enrolling
Updated: 6/16/2016
Roger Williams Medical Center
mi
from
Providence, RI
Click here to add this to my saved trials
Trial of 2nd Generation Anti-CEA Designer T Cells in Metastatic Breast Cancer
Phase Ia/Ib Trial of 2nd Generation Anti-CEA Designer T Cells in Metastatic Breast Cancer
Status: Enrolling
Updated:  6/16/2016
Tufts University Medical Center
mi
from
Boston, MA
Trial of 2nd Generation Anti-CEA Designer T Cells in Metastatic Breast Cancer
Phase Ia/Ib Trial of 2nd Generation Anti-CEA Designer T Cells in Metastatic Breast Cancer
Status: Enrolling
Updated: 6/16/2016
Tufts University Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
RDEA119 and Sorafenib Combination Dose Escalation Study
A Phase 1/2 Study of the Combination of RDEA119 and Sorafenib in Patients With Advanced Cancer
Status: Enrolling
Updated:  6/16/2016
Clinical Research Facility
mi
from
Los Angeles, CA
RDEA119 and Sorafenib Combination Dose Escalation Study
A Phase 1/2 Study of the Combination of RDEA119 and Sorafenib in Patients With Advanced Cancer
Status: Enrolling
Updated: 6/16/2016
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
RDEA119 and Sorafenib Combination Dose Escalation Study
A Phase 1/2 Study of the Combination of RDEA119 and Sorafenib in Patients With Advanced Cancer
Status: Enrolling
Updated:  6/16/2016
Clinical Research Facility
mi
from
Las Vegas, NV
RDEA119 and Sorafenib Combination Dose Escalation Study
A Phase 1/2 Study of the Combination of RDEA119 and Sorafenib in Patients With Advanced Cancer
Status: Enrolling
Updated: 6/16/2016
Clinical Research Facility
mi
from
Las Vegas, NV
Click here to add this to my saved trials
RDEA119 and Sorafenib Combination Dose Escalation Study
A Phase 1/2 Study of the Combination of RDEA119 and Sorafenib in Patients With Advanced Cancer
Status: Enrolling
Updated:  6/16/2016
Clinical Research Facility
mi
from
Albany, NY
RDEA119 and Sorafenib Combination Dose Escalation Study
A Phase 1/2 Study of the Combination of RDEA119 and Sorafenib in Patients With Advanced Cancer
Status: Enrolling
Updated: 6/16/2016
Clinical Research Facility
mi
from
Albany, NY
Click here to add this to my saved trials
RDEA119 and Sorafenib Combination Dose Escalation Study
A Phase 1/2 Study of the Combination of RDEA119 and Sorafenib in Patients With Advanced Cancer
Status: Enrolling
Updated:  6/16/2016
Clinical Research Facility
mi
from
Buffalo, NY
RDEA119 and Sorafenib Combination Dose Escalation Study
A Phase 1/2 Study of the Combination of RDEA119 and Sorafenib in Patients With Advanced Cancer
Status: Enrolling
Updated: 6/16/2016
Clinical Research Facility
mi
from
Buffalo, NY
Click here to add this to my saved trials
RDEA119 and Sorafenib Combination Dose Escalation Study
A Phase 1/2 Study of the Combination of RDEA119 and Sorafenib in Patients With Advanced Cancer
Status: Enrolling
Updated:  6/16/2016
Clinical Research Facility
mi
from
Rochester, NY
RDEA119 and Sorafenib Combination Dose Escalation Study
A Phase 1/2 Study of the Combination of RDEA119 and Sorafenib in Patients With Advanced Cancer
Status: Enrolling
Updated: 6/16/2016
Clinical Research Facility
mi
from
Rochester, NY
Click here to add this to my saved trials
RDEA119 and Sorafenib Combination Dose Escalation Study
A Phase 1/2 Study of the Combination of RDEA119 and Sorafenib in Patients With Advanced Cancer
Status: Enrolling
Updated:  6/16/2016
Clinical Research Facility
mi
from
Philadelphia, PA
RDEA119 and Sorafenib Combination Dose Escalation Study
A Phase 1/2 Study of the Combination of RDEA119 and Sorafenib in Patients With Advanced Cancer
Status: Enrolling
Updated: 6/16/2016
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
RDEA119 and Sorafenib Combination Dose Escalation Study
A Phase 1/2 Study of the Combination of RDEA119 and Sorafenib in Patients With Advanced Cancer
Status: Enrolling
Updated:  6/16/2016
Clinical Research Facility
mi
from
Greenville, SC
RDEA119 and Sorafenib Combination Dose Escalation Study
A Phase 1/2 Study of the Combination of RDEA119 and Sorafenib in Patients With Advanced Cancer
Status: Enrolling
Updated: 6/16/2016
Clinical Research Facility
mi
from
Greenville, SC
Click here to add this to my saved trials
RDEA119 and Sorafenib Combination Dose Escalation Study
A Phase 1/2 Study of the Combination of RDEA119 and Sorafenib in Patients With Advanced Cancer
Status: Enrolling
Updated:  6/16/2016
Clinical Research Facility
mi
from
Dallas, TX
RDEA119 and Sorafenib Combination Dose Escalation Study
A Phase 1/2 Study of the Combination of RDEA119 and Sorafenib in Patients With Advanced Cancer
Status: Enrolling
Updated: 6/16/2016
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
RDEA119 and Sorafenib Combination Dose Escalation Study
A Phase 1/2 Study of the Combination of RDEA119 and Sorafenib in Patients With Advanced Cancer
Status: Enrolling
Updated:  6/16/2016
Clinical Research Facility
mi
from
Tyler, TX
RDEA119 and Sorafenib Combination Dose Escalation Study
A Phase 1/2 Study of the Combination of RDEA119 and Sorafenib in Patients With Advanced Cancer
Status: Enrolling
Updated: 6/16/2016
Clinical Research Facility
mi
from
Tyler, TX
Click here to add this to my saved trials
RDEA119 and Sorafenib Combination Dose Escalation Study
A Phase 1/2 Study of the Combination of RDEA119 and Sorafenib in Patients With Advanced Cancer
Status: Enrolling
Updated:  6/16/2016
mi
from
Toronto,
RDEA119 and Sorafenib Combination Dose Escalation Study
A Phase 1/2 Study of the Combination of RDEA119 and Sorafenib in Patients With Advanced Cancer
Status: Enrolling
Updated: 6/16/2016
mi
from
Toronto,
Click here to add this to my saved trials
Bevacizumab Plus Ixabepilone to Treat Patients With Advanced Kidney Cancer
A Phase II Multi-Center Study of Bevacizumab in Combination With Ixabepilone in Subjects With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  6/16/2016
University of South Carolina
mi
from
Charlestown, SC
Bevacizumab Plus Ixabepilone to Treat Patients With Advanced Kidney Cancer
A Phase II Multi-Center Study of Bevacizumab in Combination With Ixabepilone in Subjects With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 6/16/2016
University of South Carolina
mi
from
Charlestown, SC
Click here to add this to my saved trials
Bevacizumab Plus Ixabepilone to Treat Patients With Advanced Kidney Cancer
A Phase II Multi-Center Study of Bevacizumab in Combination With Ixabepilone in Subjects With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  6/16/2016
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Bevacizumab Plus Ixabepilone to Treat Patients With Advanced Kidney Cancer
A Phase II Multi-Center Study of Bevacizumab in Combination With Ixabepilone in Subjects With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 6/16/2016
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer
A Randomized, Open Label Phase 3 Study of MM-398, With or Without 5-Fluorouracil and Leucovorin, Versus 5 Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer Who Have Failed Prior Gemcitabine-based Therapy
Status: Enrolling
Updated:  6/16/2016
Clinical Research Facility
mi
from
Henderson, NV
Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer
A Randomized, Open Label Phase 3 Study of MM-398, With or Without 5-Fluorouracil and Leucovorin, Versus 5 Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer Who Have Failed Prior Gemcitabine-based Therapy
Status: Enrolling
Updated: 6/16/2016
Clinical Research Facility
mi
from
Henderson, NV
Click here to add this to my saved trials
Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer
A Randomized, Open Label Phase 3 Study of MM-398, With or Without 5-Fluorouracil and Leucovorin, Versus 5 Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer Who Have Failed Prior Gemcitabine-based Therapy
Status: Enrolling
Updated:  6/16/2016
Clinical Research Facility
mi
from
Albuquerque, NM
Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer
A Randomized, Open Label Phase 3 Study of MM-398, With or Without 5-Fluorouracil and Leucovorin, Versus 5 Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer Who Have Failed Prior Gemcitabine-based Therapy
Status: Enrolling
Updated: 6/16/2016
Clinical Research Facility
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer
A Randomized, Open Label Phase 3 Study of MM-398, With or Without 5-Fluorouracil and Leucovorin, Versus 5 Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer Who Have Failed Prior Gemcitabine-based Therapy
Status: Enrolling
Updated:  6/16/2016
Clinical Research Facility
mi
from
Dallas, TX
Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer
A Randomized, Open Label Phase 3 Study of MM-398, With or Without 5-Fluorouracil and Leucovorin, Versus 5 Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer Who Have Failed Prior Gemcitabine-based Therapy
Status: Enrolling
Updated: 6/16/2016
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer
A Randomized, Open Label Phase 3 Study of MM-398, With or Without 5-Fluorouracil and Leucovorin, Versus 5 Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer Who Have Failed Prior Gemcitabine-based Therapy
Status: Enrolling
Updated:  6/16/2016
Clinical Research Facility
mi
from
Norfolk, VA
Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer
A Randomized, Open Label Phase 3 Study of MM-398, With or Without 5-Fluorouracil and Leucovorin, Versus 5 Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer Who Have Failed Prior Gemcitabine-based Therapy
Status: Enrolling
Updated: 6/16/2016
Clinical Research Facility
mi
from
Norfolk, VA
Click here to add this to my saved trials
Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer
A Randomized, Open Label Phase 3 Study of MM-398, With or Without 5-Fluorouracil and Leucovorin, Versus 5 Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer Who Have Failed Prior Gemcitabine-based Therapy
Status: Enrolling
Updated:  6/16/2016
Clinical Research Facility
mi
from
Gilbert, AZ
Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer
A Randomized, Open Label Phase 3 Study of MM-398, With or Without 5-Fluorouracil and Leucovorin, Versus 5 Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer Who Have Failed Prior Gemcitabine-based Therapy
Status: Enrolling
Updated: 6/16/2016
Clinical Research Facility
mi
from
Gilbert, AZ
Click here to add this to my saved trials
Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer
A Randomized, Open Label Phase 3 Study of MM-398, With or Without 5-Fluorouracil and Leucovorin, Versus 5 Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer Who Have Failed Prior Gemcitabine-based Therapy
Status: Enrolling
Updated:  6/16/2016
Clinical Research Facility
mi
from
Glendale, AZ
Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer
A Randomized, Open Label Phase 3 Study of MM-398, With or Without 5-Fluorouracil and Leucovorin, Versus 5 Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer Who Have Failed Prior Gemcitabine-based Therapy
Status: Enrolling
Updated: 6/16/2016
Clinical Research Facility
mi
from
Glendale, AZ
Click here to add this to my saved trials
Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer
A Randomized, Open Label Phase 3 Study of MM-398, With or Without 5-Fluorouracil and Leucovorin, Versus 5 Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer Who Have Failed Prior Gemcitabine-based Therapy
Status: Enrolling
Updated:  6/16/2016
Clinical Research Facility
mi
from
Scottsdale, AZ
Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer
A Randomized, Open Label Phase 3 Study of MM-398, With or Without 5-Fluorouracil and Leucovorin, Versus 5 Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer Who Have Failed Prior Gemcitabine-based Therapy
Status: Enrolling
Updated: 6/16/2016
Clinical Research Facility
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer
A Randomized, Open Label Phase 3 Study of MM-398, With or Without 5-Fluorouracil and Leucovorin, Versus 5 Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer Who Have Failed Prior Gemcitabine-based Therapy
Status: Enrolling
Updated:  6/16/2016
Clinical Research Facility
mi
from
Burbank, CA
Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer
A Randomized, Open Label Phase 3 Study of MM-398, With or Without 5-Fluorouracil and Leucovorin, Versus 5 Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer Who Have Failed Prior Gemcitabine-based Therapy
Status: Enrolling
Updated: 6/16/2016
Clinical Research Facility
mi
from
Burbank, CA
Click here to add this to my saved trials
Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer
A Randomized, Open Label Phase 3 Study of MM-398, With or Without 5-Fluorouracil and Leucovorin, Versus 5 Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer Who Have Failed Prior Gemcitabine-based Therapy
Status: Enrolling
Updated:  6/16/2016
Clinical Research Facility
mi
from
Duarte, CA
Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer
A Randomized, Open Label Phase 3 Study of MM-398, With or Without 5-Fluorouracil and Leucovorin, Versus 5 Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer Who Have Failed Prior Gemcitabine-based Therapy
Status: Enrolling
Updated: 6/16/2016
Clinical Research Facility
mi
from
Duarte, CA
Click here to add this to my saved trials
Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer
A Randomized, Open Label Phase 3 Study of MM-398, With or Without 5-Fluorouracil and Leucovorin, Versus 5 Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer Who Have Failed Prior Gemcitabine-based Therapy
Status: Enrolling
Updated:  6/16/2016
Clinical Research Facility
mi
from
Fresno, CA
Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer
A Randomized, Open Label Phase 3 Study of MM-398, With or Without 5-Fluorouracil and Leucovorin, Versus 5 Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer Who Have Failed Prior Gemcitabine-based Therapy
Status: Enrolling
Updated: 6/16/2016
Clinical Research Facility
mi
from
Fresno, CA
Click here to add this to my saved trials
Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer
A Randomized, Open Label Phase 3 Study of MM-398, With or Without 5-Fluorouracil and Leucovorin, Versus 5 Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer Who Have Failed Prior Gemcitabine-based Therapy
Status: Enrolling
Updated:  6/16/2016
Clinical Research Facility
mi
from
LaVerne, CA
Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer
A Randomized, Open Label Phase 3 Study of MM-398, With or Without 5-Fluorouracil and Leucovorin, Versus 5 Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer Who Have Failed Prior Gemcitabine-based Therapy
Status: Enrolling
Updated: 6/16/2016
Clinical Research Facility
mi
from
LaVerne, CA
Click here to add this to my saved trials
Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer
A Randomized, Open Label Phase 3 Study of MM-398, With or Without 5-Fluorouracil and Leucovorin, Versus 5 Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer Who Have Failed Prior Gemcitabine-based Therapy
Status: Enrolling
Updated:  6/16/2016
Clinical Research Facility
mi
from
San Luis Obispo, CA
Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer
A Randomized, Open Label Phase 3 Study of MM-398, With or Without 5-Fluorouracil and Leucovorin, Versus 5 Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer Who Have Failed Prior Gemcitabine-based Therapy
Status: Enrolling
Updated: 6/16/2016
Clinical Research Facility
mi
from
San Luis Obispo, CA
Click here to add this to my saved trials
Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer
A Randomized, Open Label Phase 3 Study of MM-398, With or Without 5-Fluorouracil and Leucovorin, Versus 5 Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer Who Have Failed Prior Gemcitabine-based Therapy
Status: Enrolling
Updated:  6/16/2016
Clinical Research Facility
mi
from
Boyton Beach, FL
Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer
A Randomized, Open Label Phase 3 Study of MM-398, With or Without 5-Fluorouracil and Leucovorin, Versus 5 Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer Who Have Failed Prior Gemcitabine-based Therapy
Status: Enrolling
Updated: 6/16/2016
Clinical Research Facility
mi
from
Boyton Beach, FL
Click here to add this to my saved trials
Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer
A Randomized, Open Label Phase 3 Study of MM-398, With or Without 5-Fluorouracil and Leucovorin, Versus 5 Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer Who Have Failed Prior Gemcitabine-based Therapy
Status: Enrolling
Updated:  6/16/2016
Clinical Research Facility
mi
from
Atlanta, GA
Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer
A Randomized, Open Label Phase 3 Study of MM-398, With or Without 5-Fluorouracil and Leucovorin, Versus 5 Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer Who Have Failed Prior Gemcitabine-based Therapy
Status: Enrolling
Updated: 6/16/2016
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer
A Randomized, Open Label Phase 3 Study of MM-398, With or Without 5-Fluorouracil and Leucovorin, Versus 5 Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer Who Have Failed Prior Gemcitabine-based Therapy
Status: Enrolling
Updated:  6/16/2016
Clinical Research Facility
mi
from
Kansas City, MO
Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer
A Randomized, Open Label Phase 3 Study of MM-398, With or Without 5-Fluorouracil and Leucovorin, Versus 5 Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer Who Have Failed Prior Gemcitabine-based Therapy
Status: Enrolling
Updated: 6/16/2016
Clinical Research Facility
mi
from
Kansas City, MO
Click here to add this to my saved trials
Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer
A Randomized, Open Label Phase 3 Study of MM-398, With or Without 5-Fluorouracil and Leucovorin, Versus 5 Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer Who Have Failed Prior Gemcitabine-based Therapy
Status: Enrolling
Updated:  6/16/2016
Clinical Research Facility
mi
from
St Louis, MO
Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer
A Randomized, Open Label Phase 3 Study of MM-398, With or Without 5-Fluorouracil and Leucovorin, Versus 5 Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer Who Have Failed Prior Gemcitabine-based Therapy
Status: Enrolling
Updated: 6/16/2016
Clinical Research Facility
mi
from
St Louis, MO
Click here to add this to my saved trials
Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer
A Randomized, Open Label Phase 3 Study of MM-398, With or Without 5-Fluorouracil and Leucovorin, Versus 5 Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer Who Have Failed Prior Gemcitabine-based Therapy
Status: Enrolling
Updated:  6/16/2016
Clinical Research Facility
mi
from
Buffalo, NY
Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer
A Randomized, Open Label Phase 3 Study of MM-398, With or Without 5-Fluorouracil and Leucovorin, Versus 5 Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer Who Have Failed Prior Gemcitabine-based Therapy
Status: Enrolling
Updated: 6/16/2016
Clinical Research Facility
mi
from
Buffalo, NY
Click here to add this to my saved trials
Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer
A Randomized, Open Label Phase 3 Study of MM-398, With or Without 5-Fluorouracil and Leucovorin, Versus 5 Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer Who Have Failed Prior Gemcitabine-based Therapy
Status: Enrolling
Updated:  6/16/2016
Clinical Research Facility
mi
from
Columbus, OH
Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer
A Randomized, Open Label Phase 3 Study of MM-398, With or Without 5-Fluorouracil and Leucovorin, Versus 5 Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer Who Have Failed Prior Gemcitabine-based Therapy
Status: Enrolling
Updated: 6/16/2016
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer
A Randomized, Open Label Phase 3 Study of MM-398, With or Without 5-Fluorouracil and Leucovorin, Versus 5 Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer Who Have Failed Prior Gemcitabine-based Therapy
Status: Enrolling
Updated:  6/16/2016
Clinical Research Facility
mi
from
Norman, OK
Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer
A Randomized, Open Label Phase 3 Study of MM-398, With or Without 5-Fluorouracil and Leucovorin, Versus 5 Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer Who Have Failed Prior Gemcitabine-based Therapy
Status: Enrolling
Updated: 6/16/2016
Clinical Research Facility
mi
from
Norman, OK
Click here to add this to my saved trials
Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer
A Randomized, Open Label Phase 3 Study of MM-398, With or Without 5-Fluorouracil and Leucovorin, Versus 5 Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer Who Have Failed Prior Gemcitabine-based Therapy
Status: Enrolling
Updated:  6/16/2016
Clinical Research Facility
mi
from
Greenville, SC
Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer
A Randomized, Open Label Phase 3 Study of MM-398, With or Without 5-Fluorouracil and Leucovorin, Versus 5 Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer Who Have Failed Prior Gemcitabine-based Therapy
Status: Enrolling
Updated: 6/16/2016
Clinical Research Facility
mi
from
Greenville, SC
Click here to add this to my saved trials